NASDAQ:NKTX Nkarta (NKTX) Stock Price, News & Analysis $7.04 +0.13 (+1.88%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.89▼$7.2450-Day Range$5.18▼$8.0052-Week Range$1.28▼$16.24Volume408,170 shsAverage Volume1.40 million shsMarket Capitalization$347.92 millionP/E RatioN/ADividend YieldN/APrice Target$17.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Nkarta alerts: Email Address Nkarta MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside153.3% Upside$17.83 Price TargetShort InterestBearish16.90% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.68Based on 8 Articles This WeekInsider TradingSelling Shares$27,168 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.27) to ($2.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.14 out of 5 starsMedical Sector808th out of 936 stocksPharmaceutical Preparations Industry375th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingNkarta has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNkarta has only been the subject of 3 research reports in the past 90 days.Read more about Nkarta's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.90% of the outstanding shares of Nkarta have been sold short.Short Interest Ratio / Days to CoverNkarta has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Nkarta has recently increased by 13.45%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNkarta does not currently pay a dividend.Dividend GrowthNkarta does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NKTX. Previous Next 2.0 News and Social Media Coverage News SentimentNkarta has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Nkarta this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for NKTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Nkarta to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nkarta insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,168.00 in company stock.Percentage Held by InsidersOnly 8.70% of the stock of Nkarta is held by insiders.Percentage Held by Institutions80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nkarta's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nkarta are expected to decrease in the coming year, from ($2.27) to ($2.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nkarta is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nkarta is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNkarta has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nkarta's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Nkarta Stock (NASDAQ:NKTX)Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Read More NKTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NKTX Stock News HeadlinesJuly 19, 2024 | insidertrades.comNkarta, Inc. (NASDAQ:NKTX) Insider Alicia J. Hager Sells 3,396 SharesJuly 25 at 6:36 AM | americanbankingnews.comNkarta (NASDAQ:NKTX) Receives "Buy" Rating from HC WainwrightJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! July 24 at 3:04 PM | markets.businessinsider.comBuy Rating Confirmed: Expanding Potential of Nkarta’s NKX019 in SLE TreatmentJuly 24 at 10:03 AM | sg.finance.yahoo.comBRIEF-Ley Choon Group Says Units Secured Contracts Worth S$14 MlnJuly 24 at 6:00 AM | globenewswire.comNkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus ErythematosusJuly 20, 2024 | americanbankingnews.comAlicia J. Hager Sells 3,396 Shares of Nkarta, Inc. (NASDAQ:NKTX) StockJuly 16, 2024 | globenewswire.comNkarta Announces Leadership Updates, Appoints Nadir Mahmood as PresidentJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! July 1, 2024 | investorplace.com3 Undervalued Stocks Primed for a 2X ReturnJune 27, 2024 | globenewswire.comNkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune IndicationsJune 13, 2024 | globenewswire.comNkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of DirectorsMay 18, 2024 | morningstar.comNkarta Inc Ordinary SharesMay 10, 2024 | finance.yahoo.comNkarta Inc (NKTX) Reports Q1 2024 Earnings: A Detailed Financial and Operational AnalysisMay 10, 2024 | finanznachrichten.deNkarta, Inc.: Nkarta Reports First Quarter 2024 Financial Results and Corporate HighlightsMay 10, 2024 | markets.businessinsider.comNkarta Inc. Buy Rating Affirmed Amidst Promising Clinical Studies and Robust Financial HealthMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed: Nkarta’s NKX019 Shows Promise in Lupus Nephritis Clinical TrialsMay 10, 2024 | investorplace.comNKTX Stock Earnings: Nkarta Beats EPS for Q1 2024See More Headlines Receive NKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NKTX CUSIPN/A CIK1787400 Webwww.nkartatx.com Phone925-407-1049FaxN/AEmployees140Year FoundedN/APrice Target and Rating Average Stock Price Target$17.83 High Stock Price Target$25.00 Low Stock Price Target$13.00 Potential Upside/Downside+153.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,500,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-34.13% Return on Assets-25.96% Debt Debt-to-Equity RatioN/A Current Ratio19.95 Quick Ratio19.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.56 per share Price / Book1.27Miscellaneous Outstanding Shares49,420,000Free Float45,117,000Market Cap$347.92 million OptionableOptionable Beta0.83 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Paul J. Hastings (Age 64)CEO, President & Director Comp: $935.18kMs. Alyssa Levin C.A. (Age 39)CPA, Chief Financial & Business Officer and Principal Accounting Officer Comp: $762.4kDr. David R. Shook M.D. (Age 46)Chief Medical Officer Comp: $631.55kDr. Ralph Brandenberger Ph.D. (Age 55)Chief Technical Officer Dr. James Trager Ph.D. (Age 61)Chief Scientific Officer Mr. Greg MannVice President of Public Affairs and Investor RelationsDr. Alicia J. Hager (Age 54)Chief Legal Officer & Corporate Secretary Comp: $590.94kMore ExecutivesKey CompetitorsNantKwestNASDAQ:NKFate TherapeuticsNASDAQ:FATECelyad OncologyNASDAQ:CYADPhathom PharmaceuticalsNASDAQ:PHATArcus BiosciencesNYSE:RCUSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 76,612 shares on 7/26/2024Ownership: 0.348%Catalina Capital Group LLCSold 1,861 shares on 7/24/2024Ownership: 0.024%Alicia J HagerSold 3,396 sharesTotal: $27,168.00 ($8.00/share)Simplicity Wealth LLCBought 21,659 shares on 7/10/2024Ownership: 0.076%GAMMA Investing LLCBought 4,491 shares on 7/2/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions NKTX Stock Analysis - Frequently Asked Questions How have NKTX shares performed this year? Nkarta's stock was trading at $6.60 at the beginning of 2024. Since then, NKTX shares have increased by 6.7% and is now trading at $7.04. View the best growth stocks for 2024 here. How were Nkarta's earnings last quarter? Nkarta, Inc. (NASDAQ:NKTX) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.02. When did Nkarta IPO? Nkarta (NKTX) raised $150 million in an initial public offering on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities served as the underwriters for the IPO. Who are Nkarta's major shareholders? Top institutional investors of Nkarta include Bank of New York Mellon Corp (0.35%), Simplicity Wealth LLC (0.08%), Catalina Capital Group LLC (0.02%) and GAMMA Investing LLC (0.01%). Insiders that own company stock include Ra Capital Management, LP, Simeon George, Paul J Hastings, James Trager, David Shook, Alicia J Hager, Ralph Brandenberger and Kanya Rajangam. View institutional ownership trends. How do I buy shares of Nkarta? Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Nkarta own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nkarta investors own include Axcella Health (AXLA), Cronos Group (CRON), Block (SQ), Advanced Micro Devices (AMD), ASML (ASML), Beyond Meat (BYND) and Citigroup (C). This page (NASDAQ:NKTX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NKTX Stock Alerts